Jacobs Levy Equity Management, Inc Kiniksa Pharmaceuticals, Ltd. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$10.7 - $15.79 $323,535 - $477,442	-30,237 Reduced 9.34%	293,500 $3.16 Million
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $71,843 - $107,261	6,291 Added 1.98%	323,737 $4.85 Million
Q3 2022 Nov 15, 2022	BUY	$9.76 - $13.41 $3.1 Million - $4.26 Million	317,446 New	317,446 $4.08 Million
Q3 2021 Nov 15, 2021	SELL	$11.39 - $16.23 $537,357 - $765,698	-47,178 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.22 - $19.09 $44,088 - $63,665	-3,335 Reduced 6.6%	47,178 $657,000
Q1 2021 May 17, 2021	BUY	$16.68 - $23.97 $185,464 - $266,522	11,119 Added 28.23%	50,513 $935,000
Q4 2020 Feb 16, 2021	SELL	$14.8 - $21.15 $35,312 - $50,463	-2,386 Reduced 5.71%	39,394 $696,000
Q3 2020 Nov 16, 2020	SELL	$15.21 - $25.53 $51,364 - $86,214	-3,377 Reduced 7.48%	41,780 $640,000
Q2 2020 Aug 17, 2020	SELL	$15.08 - $26.0 $65,854 - $113,542	-4,367 Reduced 8.82%	45,157 $1.15 Million
Q1 2020 May 15, 2020	SELL	$11.0 - $19.76 $89,133 - $160,115	-8,103 Reduced 14.06%	49,524 $767,000
Q4 2019 Feb 14, 2020	BUY	$5.24 - $12.96 $301,965 - $746,845	57,627 New	57,627 $637,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.